Clinical Trials Logo
  1. Home
  2. Friedreich's Ataxia
  3. NCT02179333

Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND) — STAND  

Friedreich's Ataxia Clinical Trial

Official title:
Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)

Clinical Trial Summary

The objectives of this study are: - To validate the inter-rater and intra-rater reliability of a new scale for the assessment of ataxia and neurologic dysfunction (STAND) - To assess common constructs and correlation between STAND subscale items.

Clinical Trial Description

There are few validated, comprehensive rating scales for the assessment of ataxia severity. The development of a Scale To assess Ataxia and Neurologic Dysfunction (STAND) would examine and measure as many facets of ataxia as possible. Scale items to be measured include parkinsonism, timed gait analysis, dystonia, neuropathy and peripheral nerve weakness, as well as other areas of clinical manifestation for ataxia. This brief but thorough scale should yield a thorough measurement of ataxia. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02179333
Study type Observational
Source University of South Florida
Contact
Status Completed
Phase
Start date October 2012
Completion date June 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT02660112 - (+) Epicatechin to Treat Friedreich's Ataxia Phase 2
Recruiting NCT02497534 - Biomarkers in Friedreich's Ataxia
Completed NCT04102501 - A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia Phase 3
Completed NCT01962363 - EPI-743 in Friedreich's Ataxia Point Mutations Phase 2
Completed NCT01016366 - Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia Phase 2
Recruiting NCT02069509 - Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)
Terminated NCT00803868 - Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia Phase 2/Phase 3
Completed NCT02797080 - Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia Phase 3
Completed NCT02415127 - Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Phase 3
Completed NCT00897221 - A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia Phase 2
Completed NCT02840669 - A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study) N/A
Completed NCT00697073 - Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients Phase 3
Recruiting NCT02316314 - Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)
Completed NCT00631202 - Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia Phase 2
Completed NCT01728064 - Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia Phase 2
Completed NCT02593773 - Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study Phase 3
Completed NCT01035671 - Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia Phase 2
Completed NCT00811681 - Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept Phase 3
Completed NCT00537680 - Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Phase 3
Completed NCT02445794 - A First in Human Study of RT001 in Patients With Friedreich's Ataxia Phase 1/Phase 2